BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio’s intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine. The article, “Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques,” appeared in the January 2008 edition of the journal Vaccine, whose editors tracked citations of all papers published in their journal. Dr. David B. Weiner, Professor of Pathology & Laboratory Medicine at the University of Pennsylvania and Chairman of Inovio’s Scientific Advisory Board, was the lead author of the paper.
